Research & Development

22 Nov 2019
- Drug Discovery
- Research & Development
Vor Biopharma and MaxCyte announce clinical and commercial licence agreement for engineered hematopoietic stem cells to treat cancer

By PBR Staff Writer

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCyte’s Flow Electroporation technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic.
22 Nov 2019
Drug Discovery
Research & Development
ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment

By PBR Staff Writer

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizerand Shionogi Limited as shareholders, today announced that the company will be developing the investigational broadly neutralising antibody (bNAb) N6LS for the treatment and prevention of HIV-1, as part of an exclusive licensing agreement between GSK and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
21 Nov 2019
Drug Discovery
Research & Development
Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

By PBR Staff Writer

Bristol-Myers Squibb (BMS) has completed the acquisition of US-based biotechnology company Celgene in a cash-cum-stock deal worth around $74bn.
20 Nov 2019
Drug Discovery
Research & Development
CNS Pharmaceuticals acquired worldwide rights for brain cancer drug from Houston Pharmaceuticals

By PBR Staff Writer

CNS Pharmaceuticals, a biotechnology company specializing in the development of novel treatments for brain tumors, completed an agreement with Houston Pharmaceuticals, Inc. ("HPI") to obtain the rights to a worldwide, exclusive royalty-bearing, license for the chemical compound commonly known as Berubicin.
19 Nov 2019
Drug Discovery
Research & Development
Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

By PBR Staff Writer

US-based Dicerna Pharmaceuticals and Novo Nordisk have signed a deal worth up to around $607m to discover and develop drugs for liver-related cardio-metabolic diseases.
19 Nov 2019
Drug Discovery
Research & Development
Aerie Pharmaceuticals agrees to acquire Avizorex Pharma

By PBR Staff Writer

Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, announced the signing of an agreement (the “Agreement”) for the acquisition of Avizorex Pharma, S.L. (“AVX Pharma” or “AVX”), a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.
19 Nov 2019
Drug Discovery
Research & Development
Alkermes to buy Rodin Therapeutics for up to $950m

By PBR Staff Writer

Alkermes has signed an agreement to acquire biopharmaceutical company Rodin Therapeutics in a deal valued at around $950m.
18 Nov 2019
Drug Discovery
Research & Development
Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal

By PBR Staff Writer

Roche has agreed to acquire US-based clinical-stage biotechnology company Promedior in a deal valued at around $1.39bn.
15 Nov 2019
Drug Discovery
Research & Development
EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform

By PBR Staff Writer

EpicentRx, a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has raised a $35 million Series D financing using the Silicon Valley based life-science focused investment bank, Biotech Alliances International.
14 Nov 2019
Drug Discovery
Research & Development
Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics

By PBR Staff Writer

Finch Therapeutics Group, Inc. (“Finch”) and Takeda Pharmaceutical Company Limited (“Takeda”; TSE:4502/NYSE:TAK) announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finch’s Human-First Discovery platform.

Drug Discovery

Research & Development

Teva receives FDA approval for Prolia biosimilar

uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Research & Development

Vor Biopharma and MaxCyte announce clinical and commercial licence agreement for engineered hematopoietic stem cells to treat cancer

ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment

Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

CNS Pharmaceuticals acquired worldwide rights for brain cancer drug from Houston Pharmaceuticals

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

Aerie Pharmaceuticals agrees to acquire Avizorex Pharma

Alkermes to buy Rodin Therapeutics for up to $950m

Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal

EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform

Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found